Join to View Full Profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-606-2044
Dr. Thompson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1982 - 1985- University of WashingtonResidency, Internal Medicine, 1979 - 1982
University of Alabama School of MedicineClass of 1979
Certifications & Licensure
WA State Medical License 1980 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Interleukin-2 in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1996 Jan 01
- Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Start of enrollment: 2013 Feb 15
Publications & Presentations
PubMed
- A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH).Wenwen Chen, Julia Majovski, Shailender Bhatia, Anissa Chan, Petros Grivas
The Oncologist. 2025-07-04 - Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy.Malek Shatila, Samanthika Devalaraju, Kei Takigawa, Christine Catinis, Irene Lee
Journal of the National Comprehensive Cancer Network. 2025-06-18 - 1 citationsAdjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma.Jamie S K Takayesu, Upendra Parvathaneni, George E Laramore, Neil Panjwani, Jennifer Sillings
Cancer Reports. 2025-02-01
Journal Articles
- Phase 1 Trials of Anti-ENPP3 Antibody Drug Conjugates in Advanced Refractory Renal Cell CarcinomasRoberto Pili, John A Thompson, Clinical Cancer Research
Press Mentions
Fred Hutch Phase 1 Program Director, Dr. John Thompson, RetiresDecember 19th, 2024
Multidisciplinary Approach for Addressing Immunotherapy-Related ToxicitiesJune 28th, 2019
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial ResultsMarch 18th, 2019- Join now to see all
Professional Memberships
- Member
- Member
- National Comprehensive Cancer NetworkMember
- Society for Immunotherapy of CancerMember
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
